Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Sionna Therapeutics, Inc. ( (SION) ) has provided an update.
On June 12, 2025, Sionna Therapeutics, Inc. held its Annual Meeting of Stockholders, where key decisions were made regarding the company’s leadership and financial oversight. The meeting resulted in the election of three Class I directors, Joshua Resnick, Bruce Booth, and Lucian Iancovici, to serve until 2028, and the ratification of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
The most recent analyst rating on (SION) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on Sionna Therapeutics, Inc. stock, see the SION Stock Forecast page.
More about Sionna Therapeutics, Inc.
Average Trading Volume: 169,002
Current Market Cap: $761.6M
Learn more about SION stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue